ELV vs GILD
ELV: Elevance Health is a diversified health insurer serving 45 million members through risk-based managed care plans, pharmacy, and integrated health services across medical, Medicaid, Medicare and commercial markets. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | ELV | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $420.39 | $134.84 | |
| Market cap as of 2026-07-10 | $92.0B | $166.0B | |
| P/E as of 2026-07-10 | 17.55 | 18.01 | ELV lower |
| PEG as of 2026-07-10 | 3.60 | 1.94 | GILD lower |
| Net margin as of 2026-07-10 | +2.6% | +31.0% | GILD higher |
| Gross margin as of 2026-07-10 | n/a | +79.3% | |
| Operating margin as of 2026-07-10 | +3.8% | +34.9% | GILD higher |
| ROE as of 2026-07-10 | +11.9% | +42.2% | GILD higher |
| ROA as of 2026-07-10 | +4.3% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-10 | 0.73 | 0.94 | ELV lower |
| Revenue growth (YoY) as of 2026-07-10 | +9.4% | +3.5% | ELV higher |
| Revenue CAGR (3y) SEC XBRL | +8.3% | +2.6% | ELV higher |
| Dividend yield as of 2026-07-10 | +1.7% | +2.4% | GILD higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.69 | 0.34 | |
| 1-year return as of 2026-07-09 close | +19.1% | +19.1% | GILD higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.